![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Abbott |
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00358917 |
The purpose of this study is to determine whether once-daily dosing of the lopinavir/ritonavir tablet in combination with investigator-selected nucleoside/nucleotide reverse transcriptase inhibitors will reduce viral load to very low levels in patients who have detectable viral loads with their current antiretroviral therapy.
Condition | Intervention | Phase |
HIV Infection |
Drug: lopinavir/ritonavir |
Phase III |
MedlinePlus related topics: | AIDS |
Drug Information available for: | Ritonavir Lopinavir |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment |
Official Title: | A Phase 3, Randomized, Open-Label Study of Lopinavir/Ritonavir Tablets 800/200 mg Once-Daily Versus 400/100 mg Twice-Daily When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced, HIV-1 Infected Subjects |
Enrollment: | 600 |
Study Start Date: | September 2006 |
Estimated Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
BID: Active Comparator |
Drug: lopinavir/ritonavir
tablet (400/100 mg BID)
|
QD: Experimental |
Drug: lopinavir/ritonavir
tablet (800/200 mg QD)
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
-
United States, Illinois | |||||
Global Medical Information - Abbott (1-800-633-9110) | |||||
Abbott Park, Illinois, United States, 60064 |
Abbott |
Study Director: | Thomas J Podsadecki, MD | Abbott |
Responsible Party: | Abbott ( Thomas J. Podsadecki, MD/Study Director ) |
Study ID Numbers: | M06-802 |
First Received: | July 28, 2006 |
Last Updated: | October 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00358917 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
![]() |